RKLB
Rocket Lab USA, Inc.
RKLB has a slight edge over TBI overall, supported by stronger fundamentals and stronger modeled upside.
TBI
TrueBlue, Inc.
TBI has lower modeled downside risk, despite its lower overall score.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
TBI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Weak |
TBI's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
TBI PE Valuation
TBI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TBI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TBI to return to profit, with revenue growing.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
TBI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.69 | — |
| Q3 2026 | -$1.55 | -$0.59 |
| Q2 2026 | -$1.89 | -$0.73 |
| Q1 2026 | -$1.79 | +$2.81 |
| Q4 2025 | -$1.61 | +$2.56 |
| Q3 2025 | -$0.96 | +$2.88 |
| Q2 2025 | -$1.16 | +$2.42 |
| Q1 2025 | -$4.60 | -$4.23 |
| Q4 2024 | -$4.17 | -$3.72 |
TBI is still losing money, but far less than before: $1.55 per share over the past year, against $4.60 at its worst in early 2025.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over TBI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
TBI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $520.7M | +21% |
| Q2 2026 | $443M | +12% |
| Q1 2026 | $398.6M | +7.6% |
| Q4 2025 | $418.2M | +8.3% |
| Q3 2025 | $431.3M | +13% |
| Q2 2025 | $396.3M | 0% |
| Q1 2025 | $370.3M | -8.1% |
| Q4 2024 | $386M | -22% |
TBI's revenue is recovering but still below its 2021 peak: $521M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.3% | +2.3 points |
| Q2 2026 | -0.3% | +0.5 points |
| Q1 2026 | -4.5% | -0.7 points |
| Q4 2025 | -7% | -4.3 points |
| Q3 2025 | 0% | +1.8 points |
| Q2 2025 | -0.7% | +14 points |
| Q1 2025 | -3.8% | 0 points |
| Q4 2024 | -2.7% | -1 points |
TBI has the edge over RKLB on profitability, with a higher operating margin.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has the edge over TBI on cash flow, with more consistent year-over-year improvement.
TBI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.3M | -$4.9M |
| Q2 2026 | -$24M | -$7.9M |
| Q1 2026 | -$12.6M | +$14.2M |
| Q4 2025 | -$7.5M | -978% |
| Q3 2025 | -$23.4M | -$10.7M |
| Q2 2025 | -$16.1M | -$8.3M |
| Q1 2025 | -$26.8M | -$5.2M |
| Q4 2024 | $854K | -88% |
TBI has burned cash in seven of the last eight quarters: −$72M over the past year, against −$65M the year before.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TBI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +2.2M shares |
| 1 year | +9.2% | +2.7M shares |
| 3 years | +5.5% | +1.7M shares |
| 5 years | -8% | -2.8M shares |
| Available history | -17% | -6.5M shares |
TBI has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $8,000 |
| Q3 2024 | $4.3M |
| Q2 2024 | $6.9M |
| Q1 2024 | $10.1M |
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TBI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 929.0x | High |
| Q4 2023 | -31.4x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -1.1x | Net Cash |
| Q1 2023 | -0.6x | Net Cash |
| Q4 2022 | -0.7x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
| Q2 2022 | -0.3x | Net Cash |
TBI's net debt is more than 20 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
TBI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 74.6 | Neutral |
TBI's weekly RSI is 71 (overbought) and its Stochastic is 75 (neutral).
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
TBI PE vs Industrials Sector
| Metric | TBI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
TBI has no meaningful PE right now: it lost money over the past year.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB's trend is mixed: it's above three of its five weekly moving averages, and 104% above its 200-week average.
TBI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.92 | 24% above |
| 20 week MA | $9.34 | 32% above |
| 50 week MA | $6.73 | 84% above |
| 100 week MA | $6.42 | 92% above |
| 200 week MA | $9.78 | 26% above |
TBI has the edge over RKLB on trend strength, trading above more of its moving averages.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB's yearly returns have swung widely, from +392% in 2024 to −69% in 2022. It's down 9.3% so far in 2026.
TBI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.6 | $19.2 | -19% |
| 2021 | $19.2 | $27.7 | +44% |
| 2022 | $27.7 | $19.2 | -30% |
| 2023 | $19.2 | $15.3 | -20% |
| 2024 | $15.3 | $7.87 | -49% |
| 2025 | $7.87 | $4.65 | -41% |
| 2026 YTD | $4.65 | $12.4 | +166% |
TBI has the edge over RKLB on returns for 2026, with the stronger performance.